- Celiac Disease
- About Us
- Pipeline & Trials
- News & Events
Lebanon, NJ and Bethesda, MD, September 23, 2015 — Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, announced today that Dr. Francisco Leon, CEO and Chief Medical Officer, will deliver an oral presentation on the development of non-dietary celiac disease therapies at the Kansas City Gluten & Allergen-Free Wellness Event taking place at the Kansas University Edwards Campus in Overland Park, Kansas on September 27, 2015, in conjunction with the Annual Celiac Support Association (CSA) Meeting.
Dr. Leon’s presentation entitled, “Experimental Non-Dietary Therapies Under Investigation,” is schedule to take place Sunday, September 27, 2015, from 12:40pm – 1:20pm CDT.
Dr. Leon will discuss the characteristics and mechanism of action of several investigational non-dietary treatments for celiac disease and gluten-related conditions, including AMG 714, a Phase 2-stage, anti-IL-15 monoclonal antibody that Celimmune is developing for the treatment of diet non-responsive celiac disease and refractory celiac disease type II (RCD-II), an in situ small bowel T cell lymphoma.
Dr. Leon commented, “The gluten-free diet is extremely difficult to adhere to in the modern world and is ineffective for many patients. Several approaches are being taken to develop therapies that can reduce the burden of celiac disease and help those suffering from celiac disease to stay healthy. I’m honored to be presenting at the Annual CSA Meeting and look forward to discussing investigational therapies in development for celiac disease.”
Celiac disease is a chronic hereditary systemic autoimmune disease triggered by gluten consumption. Celiac disease is characterized by damage to the lining of the small intestine, causing gastrointestinal dysfunction and debilitating symptoms. Nutritional malabsorption can lead to a failure to thrive in children and anemia and osteopenia in adults. Over the course of a lifetime, untreated or poorly managed celiac disease is often associated with deteriorating general health, multiple serious intestinal and extra-intestinal medical complications, and increased morbidity and mortality. Currently approximately 1% of Western and 0.5% of Asian populations suffer from celiac disease and the diagnosed prevalence is expected to increase dramatically with improved diagnostic tools and clinical awareness.
Celimmune LLC, a clinical development-stage immunotherapy company focused on treating and preventing autoimmune diseases, began operating in February 2015 and is headquartered in Lebanon, NJ and Bethesda, MD. Celimmune will initially focus its distinctive core competence in translational medicine, immunotherapy clinical development and commercialization on combating celiac disease and other serious autoimmune diseases.